Ottawa Hospital Research Institute – Developmental Therapeutics Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “Ottawa Hospital Research Institute – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “Ottawa Hospital Research Institute – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope
- Review of therapeutics under development by Ottawa Hospital Research Institute.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ottawa Hospital Research Institute with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of Ottawa Hospital Research Institute’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.
Reasons to buy
- Identify new drug targets and therapeutic classes in Ottawa Hospital Research Institute’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate Ottawa Hospital Research Institute’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of Ottawa Hospital Research Institute in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with Ottawa Hospital Research Institute.
- Avoid Intellectual Property Rights related issues.
Ottawa Hospital Research Institute Snapshot
Ottawa Hospital Research Institute Overview
Key Information
Key Facts
Ottawa Hospital Research Institute – Research and Development Overview
Key Therapeutic Areas
Ottawa Hospital Research Institute – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Ottawa Hospital Research Institute – Pipeline Products Glance
Ottawa Hospital Research Institute – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Ottawa Hospital Research Institute Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ottawa Hospital Research Institute – Drug Profiles
Dalteparin Sodium
Product Description
Mechanism of Action
R&D Progress
Fluviral
Product Description
Mechanism of Action
R&D Progress
Heme Iron Polypeptide (Proferrin)
Product Description
Mechanism of Action
R&D Progress
Innohep
Product Description
Mechanism of Action
R&D Progress
Leuprolide acetate
Product Description
Mechanism of Action
R&D Progress
Prednisone
Product Description
Mechanism of Action
R&D Progress
Proferrin
Product Description
Mechanism of Action
R&D Progress
(Irinotecan + Xeloda + Oxaliplatin) + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
Albumin
Product Description
Mechanism of Action
R&D Progress
Aromasin
Product Description
Mechanism of Action
R&D Progress
Autologous EMMCs
Product Description
Mechanism of Action
R&D Progress
Frozen Plasma
Product Description
Mechanism of Action
R&D Progress
Remune + ALVAC
Product Description
Mechanism of Action
R&D Progress
Filgrastim
Product Description
Mechanism of Action
R&D Progress
Nexavar + FOLFIRI
Product Description
Mechanism of Action
R&D Progress
Statin + Erlotinib
Product Description
Mechanism of Action
R&D Progress
Ottawa Hospital Research Institute – Pipeline Analysis
Ottawa Hospital Research Institute – Pipeline Products by Therapeutic Class
Ottawa Hospital Research Institute Pipeline Products By Target
Ottawa Hospital Research Institute – Pipeline Products by Route of Administration
Ottawa Hospital Research Institute – Pipeline Products by Molecule Type
Ottawa Hospital Research Institute – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Ottawa Hospital Research Institute – Pipeline by Therapy Area and Indication, 2010
Ottawa Hospital Research Institute – Pipeline by Stage of Development, 2010
Ottawa Hospital Research Institute – Monotherapy Products in Pipeline, 2010
Ottawa Hospital Research Institute – Combination Treatment Modalities in Pipeline, 2010
Ottawa Hospital Research Institute – Phase III, 2010
Ottawa Hospital Research Institute - Phase II, 2010
Ottawa Hospital Research Institute - Phase I, 2010
Ottawa Hospital Research Institute - Pipeline By Therapeutic Class, 2010
Ottawa Hospital Research Institute - Pipeline By Target, 2010
Ottawa Hospital Research Institute – Pipeline By Route of Administration, 2010
Ottawa Hospital Research Institute – Pipeline By Molecule Type, 2010 40
LIST OF FIGURES
Ottawa Hospital Research Institute – Pipeline by Therapy Area and Indication, 2010
Ottawa Hospital Research Institute – Pipeline by Stage of Development, 2010
Ottawa Hospital Research Institute – Monotherapy Products in Pipeline, 2010
Ottawa Hospital Research Institute – Combination Treatment Modalities in Pipeline, 2010
Ottawa Hospital Research Institute – Pipeline By Therapeutic Class, 2010
Ottawa Hospital Research Institute - Pipeline By Target, 2010
Ottawa Hospital Research Institute – Pipeline By Route of Administration, 2010
Ottawa Hospital Research Institute – Pipeline By Molecule Type, 2010 40
Ottawa Hospital Research Institute Overview
Key Information
Key Facts
Ottawa Hospital Research Institute – Research and Development Overview
Key Therapeutic Areas
Ottawa Hospital Research Institute – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Ottawa Hospital Research Institute – Pipeline Products Glance
Ottawa Hospital Research Institute – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Ottawa Hospital Research Institute Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ottawa Hospital Research Institute – Drug Profiles
Dalteparin Sodium
Product Description
Mechanism of Action
R&D Progress
Fluviral
Product Description
Mechanism of Action
R&D Progress
Heme Iron Polypeptide (Proferrin)
Product Description
Mechanism of Action
R&D Progress
Innohep
Product Description
Mechanism of Action
R&D Progress
Leuprolide acetate
Product Description
Mechanism of Action
R&D Progress
Prednisone
Product Description
Mechanism of Action
R&D Progress
Proferrin
Product Description
Mechanism of Action
R&D Progress
(Irinotecan + Xeloda + Oxaliplatin) + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
Albumin
Product Description
Mechanism of Action
R&D Progress
Aromasin
Product Description
Mechanism of Action
R&D Progress
Autologous EMMCs
Product Description
Mechanism of Action
R&D Progress
Frozen Plasma
Product Description
Mechanism of Action
R&D Progress
Remune + ALVAC
Product Description
Mechanism of Action
R&D Progress
Filgrastim
Product Description
Mechanism of Action
R&D Progress
Nexavar + FOLFIRI
Product Description
Mechanism of Action
R&D Progress
Statin + Erlotinib
Product Description
Mechanism of Action
R&D Progress
Ottawa Hospital Research Institute – Pipeline Analysis
Ottawa Hospital Research Institute – Pipeline Products by Therapeutic Class
Ottawa Hospital Research Institute Pipeline Products By Target
Ottawa Hospital Research Institute – Pipeline Products by Route of Administration
Ottawa Hospital Research Institute – Pipeline Products by Molecule Type
Ottawa Hospital Research Institute – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Ottawa Hospital Research Institute – Pipeline by Therapy Area and Indication, 2010
Ottawa Hospital Research Institute – Pipeline by Stage of Development, 2010
Ottawa Hospital Research Institute – Monotherapy Products in Pipeline, 2010
Ottawa Hospital Research Institute – Combination Treatment Modalities in Pipeline, 2010
Ottawa Hospital Research Institute – Phase III, 2010
Ottawa Hospital Research Institute - Phase II, 2010
Ottawa Hospital Research Institute - Phase I, 2010
Ottawa Hospital Research Institute - Pipeline By Therapeutic Class, 2010
Ottawa Hospital Research Institute - Pipeline By Target, 2010
Ottawa Hospital Research Institute – Pipeline By Route of Administration, 2010
Ottawa Hospital Research Institute – Pipeline By Molecule Type, 2010 40
LIST OF FIGURES
Ottawa Hospital Research Institute – Pipeline by Therapy Area and Indication, 2010
Ottawa Hospital Research Institute – Pipeline by Stage of Development, 2010
Ottawa Hospital Research Institute – Monotherapy Products in Pipeline, 2010
Ottawa Hospital Research Institute – Combination Treatment Modalities in Pipeline, 2010
Ottawa Hospital Research Institute – Pipeline By Therapeutic Class, 2010
Ottawa Hospital Research Institute - Pipeline By Target, 2010
Ottawa Hospital Research Institute – Pipeline By Route of Administration, 2010
Ottawa Hospital Research Institute – Pipeline By Molecule Type, 2010 40
